Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Membranous lupus nephritis.

H A Austin1, G G Illei

  • 1National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-1190, USA.

Lupus
|March 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction.

Gene therapy·2016
Same author

Immune reactivity after adenoviral-mediated aquaporin-1 cDNA transfer to human parotid glands.

Oral diseases·2016
Same author

TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

Oral diseases·2012
Same author

Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.

Oral diseases·2011
Same author

Helicobacter pylori and autoimmune diseases.

Oral diseases·2011
Same author

Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjögren's syndrome.

Oral diseases·2011
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Membranous lupus nephritis (MLN) affects 20% of lupus patients, often causing comorbidities but rarely end-stage renal disease. Early treatment focuses on proteinuria and cardiovascular risk factors, with immunosuppression for severe cases.

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Membranous lupus nephritis (MLN) accounts for approximately 20% of lupus-related renal disease.
  • Pathogenesis of MLN is not fully understood, with current understanding extrapolated from idiopathic membranous nephritis and proliferative lupus nephritis.
  • Historical diagnostic criteria changes complicate natural history and treatment descriptions.

Purpose of the Study:

  • To review the current understanding of membranous lupus nephritis (MLN).
  • To discuss the natural history, prognosis, and management strategies for MLN.
  • To highlight the need for prospective controlled trials in MLN.

Main Methods:

  • Literature review and synthesis of existing studies on membranous lupus nephritis (MLN).

Related Experiment Videos

  • Extrapolation of pathogenetic mechanisms from related kidney diseases and animal models.
  • Analysis of natural history data and clinical observations.

    • Main Results:

    • MLN typically shows a low progression rate to end-stage renal disease.
    • Significant comorbidities are common in patients with MLN.
    • Current treatment recommendations include early intervention with angiotensin antagonists and management of cardiovascular risk factors.

    Conclusions:

    • Early management of proteinuria and cardiovascular risk factors is crucial for patients with MLN.
    • Immunosuppressive therapies may be considered for persistent nephrotic syndrome.
    • Prospective controlled trials are essential to establish evidence-based clinical practice guidelines for MLN treatment.